Novo Nordisk faces shareholder fraud lawsuit over undisclosed dosing changes in CagriSema Phase 3 trial

New Jersey federal judge Robert Kirsch ruled that shareholders can pursue claims that Novo Nordisk misled investors about its Phase 3 study of the weight‑loss drug CagriSema.

The plaintiffs allege Novo failed to disclose a protocol amendment in the REDEFINE‑1 trial that let patients adjust their own dose, a change that led to fewer than 60% of participants completing dose escalation and reaching the highest dose level.

Investors contend the omission created a false impression of the drug's tolerability and success prospects, causing them to purchase Novo shares at artificially inflated prices. Novo will now have to answer the fraud allegations in court.